QR-Code

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

<p>Abstract</p> <p>Background</p> <p>Lenalidomide treatment in myelodysplastic syndrome (MDS) may lead to thrombocytopenia and dose reductions/delays. This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and its effects on the incidence of clinically significant...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Wang Eunice S, Lyons Roger M, Larson Richard A, Gandhi Sunil, Liu Delong, Matei Carmen, Scott Bart, Hu Kuolung, Yang Allen S
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMC 2012-11-01
Schriftenreihe:Journal of Hematology & Oncology
Schlagworte:
Romiplostim
Lenalidomide
Thrombocytopenia
Myelodysplastic syndrome
Online-Zugang:http://www.jhoonline.org/content/5/1/71
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge